<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127592</url>
  </required_header>
  <id_info>
    <org_study_id>ETCAPS0317OR-III</org_study_id>
    <nct_id>NCT03127592</nct_id>
  </id_info>
  <brief_title>Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction</brief_title>
  <acronym>FDCETCB-III</acronym>
  <official_title>Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apsen Farmaceutica S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apsen Farmaceutica S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III study will compare the efficacy and tolerability of a Fixed Dose Combination
      of Etodolac + Cyclobenzaprine versus the isolated drugs in postoperative pain control after
      impacted third molar extraction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Superiority of the Fixed Dose Combination versus Isolated active substances</measure>
    <time_frame>4 hours</time_frame>
    <description>The Primary outcome will be accessed by the individual response rate in relation to the pain intensity calculated by the Visual Analogic Scale (VAS) scale performed after 4 hours of administration of the first dose of medicines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual response rate</measure>
    <time_frame>6h, 12h, 24h, 48h and 72h</time_frame>
    <description>Individual response rate in relation to the evaluation of pain intensity calculated through the Visual Analogic Scale (VAS) measure in times 6h, 12h, 24h, 48h and 72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edema</measure>
    <time_frame>4 hours</time_frame>
    <description>Absence of edema after 4 hours of drug administration and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mandibula constriction</measure>
    <time_frame>4 hours</time_frame>
    <description>Absence of mandibular constriction after 4 hours of drug administration and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>3 days</time_frame>
    <description>Proportion of participants requiring the use of rescue medication over the 3 days of treatment in each treatment group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Pain, Acute</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 active treatment (Fixed Dose Combination) + 2 placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 active treatment (Cyclobenzaprine) + 2 placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 active treatment (Etodolac) + 2 placebos</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Dose Combination</intervention_name>
    <description>Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etodolac</intervention_name>
    <description>Individual drug</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Flancox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclobenzaprine</intervention_name>
    <description>Individual drug</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Miosan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy research participants of both sexes (male and female non-pregnant), aged 18
             years or over, underwent impacted third molar extraction surgery

        Exclusion Criteria:

          -  Presence of any event and / or pathology at the site of interest that may interfere
             with and contraindicate the performance of the surgical procedure at the discretion of
             the Investigator, including periodontitis, odontogenic tumors or cysts (associated or
             not with the third molar), trauma, presence of Inflammation and / or infection;

          -  Present or past history of any cardiac, gastrointestinal, respiratory, hepatic, renal,
             endocrine, neurological, metabolic, psychiatric, hematological event;

          -  Previous diagnosis of alcohol and drug abuse defined by DSM-V;

          -  Current or past history (for less than 12 months) of smoking;

          -  Use of illicit drugs;

          -  History of bleeding / bleeding or coagulation disorders, gastric ulcer and / or active
             peptic hemorrhage;

          -  Any finding of clinical (clinical / physical), laboratory or cardiac evaluation (ECG)
             observation that is interpreted by the investigating physician as a risk to the
             participant;

          -  Use of drugs that potentially interfere with the kinetics / dynamics of acetaminophen
             or any other medicinal product considered clinically significant by the Investigator;

          -  Known hypersensitivity to the active principles used during the study (etodolac and
             cyclobenzaprine);

          -  Women in gestation or breastfeeding, as well as women who present a positive pregnancy
             test (β - hCG) during the study screening / selection period;

          -  Professionals directly involved in the realization of the present study and their
             relatives;

          -  Participant of the research that has participated in clinical study protocols in the
             last 12 (twelve) months, unless the Investigator deems that there may be direct
             benefit to it.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclobenzaprine</mesh_term>
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Etodolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

